Catherine C. Coombs

5.8k total citations · 1 hit paper
65 papers, 1.4k citations indexed

About

Catherine C. Coombs is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Catherine C. Coombs has authored 65 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Genetics, 36 papers in Hematology and 13 papers in Pathology and Forensic Medicine. Recurrent topics in Catherine C. Coombs's work include Chronic Lymphocytic Leukemia Research (30 papers), Acute Myeloid Leukemia Research (28 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (14 papers). Catherine C. Coombs is often cited by papers focused on Chronic Lymphocytic Leukemia Research (30 papers), Acute Myeloid Leukemia Research (28 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (14 papers). Catherine C. Coombs collaborates with scholars based in United States, Australia and United Kingdom. Catherine C. Coombs's co-authors include Martin S. Tallman, Ross L. Levine, Montreh Tavakkoli, Ahmet Zehir, Michael F. Berger, Marc Ladanyi, David M. Hyman, José Baselga, Maria E. Arcila and David B. Solit and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Catherine C. Coombs

61 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes

2017 521 citations Catherine C. Coombs, Ahmet Zehir et al. Cell stem cell profile →

Peers

Catherine C. Coombs

HEMAT

GENET

ONCOL

Pinkal Desai United States

Jamile M. Shammo United States

Parameswaran Venugopal United States

Andrea Kündgen Germany

Maro Ohanian United States

Lauren E. Damon United States

Jennifer Dunlap United States

Marek Hus Poland

Pascal Mossuz France

R. Pieters Netherlands

Pinkal Desai United States

Catherine C. Coombs

679 ×0.8

HEMAT

398 ×0.8

308 ×0.7

GENET

371 ×1.0

198 ×0.7

ONCOL

Citations per year, relative to Catherine C. Coombs Catherine C. Coombs (= 1×) peers Pinkal Desai

Countries citing papers authored by Catherine C. Coombs

Since Specialization

Citations

This map shows the geographic impact of Catherine C. Coombs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine C. Coombs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine C. Coombs more than expected).

Fields of papers citing papers by Catherine C. Coombs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine C. Coombs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine C. Coombs. The network helps show where Catherine C. Coombs may publish in the future.

Co-authorship network of co-authors of Catherine C. Coombs

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine C. Coombs. A scholar is included among the top collaborators of Catherine C. Coombs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine C. Coombs. Catherine C. Coombs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ávila, José Carlos Martínez & Catherine C. Coombs. (2025). What’s hidden in plain sight? Impact of clonal hematopoiesis on the risk and progression of non-hematologic cancers. Haematologica.

Virani, Salim S., Job A.J. Verdonschot, Catherine C. Coombs, et al.. (2024). Clonal hematopoiesis of indeterminate potential and cardiovascular disease: Pathogenesis, clinical presentation, and future directions. Progress in Cardiovascular Diseases. 86. 79–85. 3 indexed citations

Roeker, Lindsey E., Jennifer A. Woyach, Chan Y. Cheah, et al.. (2024). Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial. Blood. 144(13). 1374–1386. 11 indexed citations

Stephens, Deborah M., Chris Stewart, Catherine C. Coombs, et al.. (2024). Feasibility of Discontinuation of Bruton's Tyrosine Kinase Inhibitors in Patients with Chronic Lymphocytic Leukemia: A Patient Survey. Blood. 144(Supplement 1). 7743–7743.

Jain, Nitin, Catherine C. Coombs, James D’Olimpio, et al.. (2024). Preliminary Results from a Phase 1b Study of Non-Covalent Pan-Mutant BTK Inhibitor Docirbrutinib (AS-1763) in Patients with Previously Treated B-Cell Malignancies. Blood. 144(Supplement 1). 1866–1866.

Muehlenbein, Catherine E., Catherine C. Coombs, Nirav N. Shah, et al.. (2023). CT-166 Long-Term Safety With ≥12 Months of Pirtobrutinib in Relapsed/Refractory B-Cell Malignancies. Clinical Lymphoma Myeloma & Leukemia. 23. S520–S520. 1 indexed citations

Jain, Nitin, James D’Olimpio, Seung‐Tae Lee, et al.. (2023). Trial in Progress: A Phase 1b Study of AS-1763, an Oral, Potent and Selective Noncovalent BTK Inhibitor, in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma. Blood. 142(Supplement 1). 3288–3288. 1 indexed citations

Coombs, Catherine C., et al.. (2023). Cellular Therapies in Chronic Lymphocytic Leukemia and Richter’s Transformation: Recent Developments in Chimeric Antigen Receptor T-Cells, Natural Killer Cells, and Allogeneic Stem Cell Transplant. Cancers. 15(6). 1838–1838. 3 indexed citations

Jensen, Jeffrey L., et al.. (2023). Clonal Hematopoiesis and the Heart: a Toxic Relationship. Current Oncology Reports. 25(5). 455–463. 2 indexed citations

10.

Coombs, Catherine C., et al.. (2023). SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia. 23(10). 697–704. 5 indexed citations

11.

Jensen, Jeffrey L., David W. Hillman, Glenn Heller, et al.. (2023). Clonal hematopoiesis in the phase 3 Alliance A031201 trial of metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor (AR)-targeted therapies.. Journal of Clinical Oncology. 41(16_suppl). 5021–5021. 1 indexed citations

12.

Meier, Jeremy D., Jeffrey L. Jensen, Christopher Dittus, Catherine C. Coombs, & Samuel M. Rubinstein. (2022). Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma. Blood Reviews. 56. 100986–100986. 7 indexed citations

13.

Miyahira, Andrea K., Jelani C. Zarif, Catherine C. Coombs, et al.. (2021). Prostate cancer research in the 21st century; report from the 2021 Coffey‐Holden prostate cancer academy meeting. The Prostate. 82(2). 169–181. 5 indexed citations

14.

Deal, Allison M., et al.. (2021). Impact of Adherence to Ibrutinib on Clinical Outcomes in Real-World Patients With Chronic Lymphocytic Leukemia. Journal of the Advanced Practitioner in Oncology. 12(1). 20–28. 2 indexed citations

15.

Tschernia, Nicholas, Vaibhav Kumar, Dominic T. Moore, et al.. (2021). Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia. Transplantation and Cellular Therapy. 27(12). 1021.e1–1021.e5. 17 indexed citations

16.

Zeidner, Joshua F., Benjamin G. Vincent, Anastasia Ivanova, et al.. (2017). Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood. 130. 1349–1349. 10 indexed citations

17.

Coombs, Catherine C., Ahmet Zehir, Sean M. Devlin, et al.. (2017). Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell stem cell. 21(3). 374–382.e4. 521 indexed citations breakdown →

18.

Coombs, Catherine C., Montreh Tavakkoli, & Martin S. Tallman. (2015). Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer Journal. 5(4). e304–e304. 187 indexed citations

19.

Coombs, Catherine C., Martin S. Tallman, & Ross L. Levine. (2015). Molecular therapy for acute myeloid leukaemia. Nature Reviews Clinical Oncology. 13(5). 305–318. 98 indexed citations

20.

Coombs, Catherine C., Lorenzo Falchi, J. Brice Weinberg, Alessandra Ferrajoli, & Mark C. Lanasa. (2012). Chronic lymphocytic leukemia in African Americans. Leukemia & lymphoma. 53(11). 2326–2329. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact